AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
TG Therapeutics CEO to Participate in H.C. Wainwright Global Investment Conference.
ByAinvest
Thursday, Sep 4, 2025 7:35 am ET1min read
TG Therapeutics announced that CEO Michael S. Weiss will participate in the H.C. Wainwright 27th Annual Global Investment Conference on September 8-10, 2025. Weiss will be part of a fireside chat on September 8 at 10:30am ET, and a live webcast will be available on the company's website.
New York, Sept. 02, 2025 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX) has announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the H.C. Wainwright 27th Annual Global Investment Conference, scheduled to take place in New York, NY from September 8 to 10, 2025. The fireside chat, featuring Weiss, is set for Monday, September 8, at 10:30 am ET. A live webcast of the event will be available on the company's website.The H.C. Wainwright 27th Annual Global Investment Conference is a prominent event that brings together leading investment professionals, analysts, and industry experts. Weiss's participation provides an opportunity for investors and financial professionals to gain insights into TG Therapeutics' strategic direction, recent developments, and future prospects.
TG Therapeutics is a fully integrated, commercial-stage biopharmaceutical company focused on the development and commercialization of novel treatments for B-cell diseases. The company has received approvals from the U.S. Food and Drug Administration (FDA) and other regulatory bodies for its product BRIUMVI® (ublituximab-xiiy) for the treatment of multiple sclerosis and other related conditions.
For more information, visit the company's website at [www.tgtherapeutics.com](http://www.tgtherapeutics.com) or follow them on X (formerly Twitter) @TGTherapeutics and LinkedIn.
[1] https://www.stocktitan.net/news/TGTX/tg-therapeutics-to-participate-in-the-h-c-wainwright-27th-annual-lxro2ueup5py.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet